My thoughts on AHZ, page-8

My thoughts on the transformation of ADMEDUS from a dead duck eighteen months ago to the leading BIO/MANUFACTURING TISSUE CONGLOMERATE in the world.

WP's thoughts Turning around a company that was in such serious trouble and getting it firing on all cylinders is not a quick fix but we are definitely on the right track now building a bankable business for the longer-term.
I am bullish on the RNA assets, particularly in the oncology arena (head and neck cancer combination with a check point inhibitor).

My focus has been on profit from day 1 – it’s unrelenting and I am not flexible on achieving our commitments to the market in the time prescribed.
. I am personally very excited by the sheer scale of our commercial opportunities with regards to the different projects in front of us. The tissue business is certainly competitive, but we will dominate the space as the snowball picks up momentum due to our clinical superiority and unique products such as CardioCel 3D.

to a safe and bankable global healthcare company with highly valuable commercial assets and clinically superior products.

We are at the beginning of an exceptional Aussie success story which will go well beyond my tenure will have generational value.




I will do a webinar in September once our full year results are available, with a full update in November at the AGM.

(i.e. we really need to consider AHZ as a new company in a new space from Code Red onward).

ADMEDUS'S future is assured.

PS. And if I'm over the TOP then WP. must be an astronaut.